Details for New Drug Application (NDA): 215599
✉ Email this page to a colleague
NDA 215599 describes FLECAINIDE ACETATE, which is a drug marketed by Amneal Pharm, Ani Pharms, Aurobindo Pharma Ltd, Beximco Pharms Usa, Chartwell, Hikma, Sun Pharm Inds Ltd, and Yichang Humanwell, and is included in nine NDAs. It is available from fifteen suppliers. Additional details are available on the FLECAINIDE ACETATE profile page.
The generic ingredient in FLECAINIDE ACETATE is flecainide acetate. There are ten drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the flecainide acetate profile page.
The generic ingredient in FLECAINIDE ACETATE is flecainide acetate. There are ten drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the flecainide acetate profile page.
Summary for 215599
| Tradename: | FLECAINIDE ACETATE |
| Applicant: | Yichang Humanwell |
| Ingredient: | flecainide acetate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 215599
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| FLECAINIDE ACETATE | flecainide acetate | TABLET;ORAL | 215599 | ANDA | Epic Pharma, LLC | 42806-817 | 42806-817-01 | 100 TABLET in 1 BOTTLE (42806-817-01) |
| FLECAINIDE ACETATE | flecainide acetate | TABLET;ORAL | 215599 | ANDA | Epic Pharma, LLC | 42806-818 | 42806-818-01 | 100 TABLET in 1 BOTTLE (42806-818-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 50MG | ||||
| Approval Date: | Sep 8, 2022 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 100MG | ||||
| Approval Date: | Sep 8, 2022 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 150MG | ||||
| Approval Date: | Sep 8, 2022 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
